Get started
Nektar TherapeuticsNN

Nektar Therapeutics

0.8612USDR
+0.0033+0.38%
Last update at Mar 6, 23:08 GMT
0.8860USD
+0.0248+2.88%
No tradesPre-marketLast update at 14:01 GMT
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

NKTR trade ideas

Nektar Therapeutics (NKTR) - Get in under right conditionsCompany info: Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. This stock has been beaten down but has large institutional buys in it so make it suspectable to high downside volatility, be careful. Volatility can act both ways! Looking for a RS or J Hook to get in. Target would be around 0.99 and will decide then if to hold or sell or take profits off and let it run. (if it goes there of course!)
NASDAQ:NKTRLong
by Kemsdale
2
NKTR High Tight Flag- Pre-Earnings High Flyer LONGNKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered to be predictive of another leg up of similar magnitude. I will be watching this in the premarket upcoming and also at the report of earnings. I hope to catch a decent ride. If I do get it I will quit the ride as soon as the indicators flip signals. This could be a good one. Buyer anticipation and sentiment could yield great profit in little time the money is exposed to the market.
NLong
by AwesomeAvani
3
$NKTR BULLISH PRICE ACTION PREEMPTS TRIAL DATA The stock of NKTR has been setting up nicely for a breakout and June 13th could be the day it happens, as the company will be hosting a analysts conference call to discuss trial results/data. Keep on strong watch for explosive moves. AVERAGE ANALYSTS PRICE TARGET $69.50 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT SHORT INTEREST 12.65% P/E RATIO 9.54 Nektar Therapeutics (NKTR -0.6%) will host a conference call for analysts and investors on Thursday, June 13, at 8:00 am ET to discuss Phase 1a data on NKTR-358 in healthy volunteers. The results will be presented at EULAR in Madrid. NKTR-358 is a regulatory T cell stimulator in development for autoimmune disorders. COMPANY PROFILE Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
NLong
by DEXWireNews
Nektar Therapeutics (NASDAQ: $NKTR) Ready To Kick Cancer's Azz🦵Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
NLong
by RedHotStocks
2
NKTR was a top gainer, rising +40.26%. Expect Uptrend reversalNektar Therapeutics (NKTR, $22.82) was one of top quarterly gainers, jumping +40.26% to $22.82 per share. My A.I.dvisor analyzed 169 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 156 of them (92.52%) charted an Uptrend while 13 of them (7.48%) trended down.My A.I.dvisor found 426 similar cases when NKTR's price went up 15% within three months. In 218 out of those 426 cases, NKTR's price went down during the following month. Based on these historical data, my A.I. thinks the odds of an Uptrend reversal for NKTR are 51%.
NLong
by tickeronAI
1
Nektar is reaching fair valueNektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance). The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm expecting the stock price to consolidate around $23 level. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor. Don't forget to support this idea, if you liked it, and to follow me here on TradingView. Investing Fellow
N
by Investing_Fellow
1
Historical Chart; Picking numbers in the range for 3/2020 In my previous idea dated 12/21/2018, "NKTR SHORT 1-Year, Historical supports show more downside.", I pegged a bottom support at $16. (I realize it dropped slightly below that last month). On 12/26/2018, I updated the idea to give a range for 12/31/2019, "Bullish/Bearish Outlook Dec 30th, 2019", pegging a Bearish sentiment at ~$16.32 and Bullish sentiment at ~$36.19 for 12/31/2019. (Within range) I listen to the Earnings Calls, although, I admit, I am at a loss with most of the terminology and technology. This week's call v. last quarter's was a huge difference in the overall sentiment coming from CEO Howard Robin. In this call, Mr. Robin, along with all others on the call, had an encouraging vibe, with positive R&D updates, increased Phase developments within their pipeline, and as mentioned earlier in the week, regulatory committees picking up the review of NKTR 181 (www.nektar.com), to be reviewed in "the next few months". This morning I am taking a wide shot look at Nektar's history, and preparing ranges for where the stock may go from here: Bearish sentiment supports: ~$13.42 ~$16.33 Bullish sentiment supports: ~$20.47 ~$25.29 (7-day moving average) ~$27.99 ~$32.57 ~$44.82 (29-day moving average) Please leave a comment, idea, constructive criticism, question, or hilarious joke to help with my growth and education. I am NOT a financial advisor, CPA, or any other sort of person you should "Take to the Bank." Do your own research. God gave you a mind of your own, use it. I am an individual investor with three NKTR options (1 Sell at $75/sh, 2 Buys at $8 and $20) contracts expiring 1/17/2019 and 21 shares ($17.98/avg cost), at this time. I share my ideas on Tradingview to lockdown my own thoughts on the product and have to look back on. If my ideas help you, GREAT!! If not, oops. Happy hunting.
NLong
by QUINNsNextStep
2
Nektar should test 21.34 on earnings strength and might fill gapNektar Therapeutics got a big upside surprise on its earnings report for both earnings and revenue. With earnings and revenue trending up, $21-22 is a fair price for the stock given analyst estimates from before the earnings report. There's resistance at 21.34, so we may initially get rejected from that level. In the near-to-mid-term, however, the earnings beat should lead analysts to revise their forecasts upward. Depending on the size of the revisions, Nektar could attempt a gap fill up to 27.85. (Average analyst price target is over $29.)
NLong
by ChristopherCarrollSmith
$NKTR Gap fill trade in Nektar TherapeuticsEntry level $22.25 = Target price $28.00 = Stop loss $21.00 Trade the huge gap in the chart Stock is well below its average analysts price target @$31 and overweight rating. Short interest 19.87% fuel a recovery rally. Company profile Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
NLong
by Bullishcharts
NKTR Gaining Steam. With all the opioid lawsuits against drug manufactors NKTR stands as a clear choice for massive future gains. Why? NKTR has made a non-addictive opioid pending FDA Approval. Everyday 130 people die from overdosing on some form of opioid which is why creating a safe, non-addictive opioid is a huge feat. This stock is at an incredible value, and the risk v reward is highly favored toward reward. If this company gets FDA approval for this drug it will skyrocket back to previous highs of 100+. I'm in for the long term, but there are plenty of short term opportunites here. Don't miss out on this incredible opportunity! FDA approval date is unknown and was pushed back due to on-going lawsuits regarding opioids in general. NKTR-181 (loxicodegol) is a novel mu-opioid agonist molecule designed to have a slow rate of entry into the brain thus reducing abuse potential and CNS-mediated side effects. NKTR-181 is in development for the treatment of chronic low back pain in adult patients new to opioid therapy. Do your own research.
NLong
by st0nkz
NKTR August Prediction.NKTR is a bio-pharmaceutical company that has a large pipeline. News: July 25th FDA issues letter postponing a Advisory Committee meeting (ADCOM) on their pain relief drug, the postponement is not related to the specific drug itself price drops. Aug 1st: Breakthrough Therapy Designation given for metastatic melanoma drug Aug 8th Earnings Report - expect a sell off at ER based on coming week's action. Could be a good time to load up before PDUFA Aug 29: PDUFA still scheduled. My Plan: Basically NKTR got hit with a letter from the FDA knocking it out of it's triangle. Now with good news about the Breakthrough therapy designation it is possibly taking back lost ground. This could be a good chance to get in this company before the Aug 29 PDUFA. Warning: Biotech stocks have high volatility and are unpredictable which is the nature of the biotech market. Please trade at your own risk. This is just an idea.
NLong
by Cream4349
US Stock Advisor: Long NKTRLong term trend : uptrend on the monthly chart. Short term trend : downtrend on a weekly chart. Chart formation : price coiling with support formation; reversal formation on the daily chart Supply and demand : overbought with low stochastics Opportunity : long-term BUY. Can buy now or wait for the price to retrace 1 more time towards 32. Rules : Always follow the strategy. Respect your stop loss. Follow risk-management methods. Target is variable on market conditions. Best
NLong
by USInvestmentAdvisor